Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

A Novel Bioluminescent Immunoassay for Detecting SARS-CoV-2 Antibodies

In this webinar, you will learn:

  • How the Lumit™ Immunoassay Technology works
  • The clinical performance of the Lumit™ Dx SARS-CoV-2 Immunoassay 
  • The benefits of Lumit™ Immunoassay Technology and how it can increase testing capacity

Summary

COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 and was declared a pandemic by WHO (World Health Organization) on March 11, 2020.  A key to containing the spread of COVID-19 is the ability to understand the true extent of COVID-19 infection by identifying asymptomatic cases as well as individuals who have antibodies against SARS-CoV-2,which may indicate whether individuals had been exposed to, and mounted an immune response to, the virus. Serological tests that can detect antibodies against SARS-CoV-2 can be important in understanding the prevalence and aid in designing containment strategies for this deadly disease.

In this webinar Nidhi Nath, PhD will discuss the features of the Lumit™ Dx SARS-CoV-2 Immunoassay, which is a simple, reliable, no-wash alternative to conventional ELISAs designed for qualitative detection of SARS-CoV-2 antibodies in serum or plasma. He will also discuss the clinical sensitivity (PPA) of the Lumit™ Dx Immunoassay which was stratified based on days post onset of symptoms using samples collected from subjects who tested positive for SARS-CoV-2 with an RT-PCR method and experienced  varying levels of disease. In addition, Dr. Nath will discuss the clinical specificity (NPA) of the Lumit™ Immunoassay, as determined using sampled collected prior to January 2020 as well as samples collected from subjects exhibiting other illnesses.


Speaker

1925-nath-nidhi-125x124-v2

Nidhi Nath, PhD
Senior Research Scientist

Nidhi Nath is a Group Leader in R&D at Promega, leading development of new products and technologies for antibody and protein enrichment, characterization, and applications. Currently, his group is developing novel immunoassay platforms using NanoLuc and Lumit technologies.

Prior to joining Promega, Dr. Nath was a Research Assistant Professor at Department of Biomedical Engineering at Duke University, where he developed nanoparticle based biosensors and designed novel materials for biological assays. Dr. Nath received his Ph.D. from Center for Biomedical Engineering at Indian Institute of Technology, Delhi and completed post-doctoral studies at Department of Pharmacology, University of Maryland.

We love to talk science.

Sign up to receive monthly invitations to our webinars.

Sign Up